Metis Partners was appointed by PwC to support the marketing and sale of the IP assets relating to Viragen.
Viragen was a highly innovative bio-pharmaceutical company that researched, developed and manufactured therapeutic proteins for the treatment of cancer and viral diseases. The Company operated internationally with operations in the US, Scotland and Sweden and had attracted almost $10m investment.
IP Assets Sold
- International patent portfolio protecting highly innovative bio-tech
- Documented and transferable organizational knowledge
- Goodwill rights in the brand and reputation
Highlight of this IP Sale
We had unique experience of selling IP in this sector and were able to effectively communicate the value of this highly innovative patent portfolio and complementary IP assets to secure a high-five figure sum. Our upfront IP diligence was thorough, helping to ensure there was no opportunity for purchasers to price chip during the lengthy legal completion process.